Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,118.00
Bid: 12,120.00
Ask: 12,124.00
Change: 68.00 (0.56%)
Spread: 4.00 (0.033%)
Open: 11,966.00
High: 12,162.00
Low: 11,966.00
Prev. Close: 12,050.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-EU rejects accusations of 'vaccine nationalism'

Tue, 09th Mar 2021 15:41

(Adds British government reaction)

By John Chalmers

BRUSSELS, March 9 (Reuters) - European Council President
Charles Michel on Tuesday rejected charges of "vaccine
nationalism" levelled against the EU, saying that while Britain
and the United States have outright bans on exports of COVID-19
shots, the EU had not stopped exporting.

The EU has found itself under fire at home for a vaccine
roll-out much slower than those of former member Britain or the
United States, and abroad for so far doing less than China,
Russia or India to supply vaccines to poor countries.

Last week it annoyed vaccine buyers abroad by endorsing an
Italian decision to halt a shipment to Australia.

Britain had a quick retort for the comments by Michel, who
represents the 27 European Union member states, saying it has
not blocked the export of a single COVID-19 vaccine.

"Any references to a UK export ban or any restrictions on
vaccines are completely false," a UK government spokesman said.

In a lengthy statement Michel laid out a defence of the
bloc's strategy. He said that without Europe, it would not have
been possible to develop and produce several vaccines in less
than a year, and EU solidarity had ensured that poorer countries
of the bloc received their first doses.

He took aim at the "highly publicised" supply of vaccines by
China and Russia to other countries.

"We should not let ourselves be misled by China and Russia,
both regimes with less desirable values than ours, as they
organise highly limited but widely publicised operations to
supply vaccines to others." Michel also noted that China and
Russia had both vaccinated fewer people at home than the EU.

"Europe will not use vaccines for propaganda purposes. We
promote our values," he said.

Michel also defended a system to control the export of doses
produced in EU countries, invoked by Italy last week to block a
shipment of AstraZeneca shots to Australia.

"Our objective: to prevent companies from which we have
ordered and pre-financed doses from exporting them to other
advanced countries when they have not delivered to us what was
promised," Michel said. "The EU has never stopped exporting."

He said the EU would become the world's leading vaccine
producer in the coming months and was the best equipped to adapt
vaccine output quickly to virus mutations.

The British government's rebuff of Michel's comments came at
a time of growing tensions between London and Brussels following
the completion of Britain's exit from the EU at the end of 2020.

Relations strained by years of bruising talks over Brexit
took a turn for the worse in January when the EU briefly
threatened to use emergency measures to stop coronavirus
vaccines going from the bloc into Northern Ireland, a
British-ruled province bordering EU member state Ireland.

"This pandemic is a global challenge and international
collaboration on vaccine development continues to be an integral
part of our response," the British government spokesman said.

(Additional reporting by Elizabeth Piper and Costas Pitas in
London
Editing by Mark Heinrich)

More News
Today 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
Today 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.